Drug Licensed from Sanofi Becomes First FDA-Approved Therapy for Ultra-Rare Primary Immunodeficiency
The FDA approved X4 Pharmaceuticals drug Xolremdi for treating WHIM syndrome. The molecule, which addresses the underlying cause of this rare immunodeficiency, was licensed from Sanofi’s Genzyme subsidiary.
Pivot Podcast: A Conversation with Capital Rx CEO A.J. Loiacono
Season 2 of the MedCity Pivot Podcast has launched with a special focus on the evolution of pharmacy and pharmacy benefit management. The first guest this season is A.J. Loiacono, who leads Capital Rx.
Navigating Healthcare’s New Era of Algorithmic Transparency
What EHR/EMR vendors need to know to comply with ONC’s HTI-1 final rule
Ono Pharma’s Plan to Become a Global Player Picks Up a New Piece With $2.4B Deciphera Acquisition
Ono Pharmaceutical’s acquisition of Deciphera Pharmaceuticals adds to a cancer drug pipeline that already spans multiple modalities. Deciphera develops drugs that target the on-off switch of enzymes that drive cancer cell growth.
Inequity in Interoperability: The Haves and Have-Nots & How QHINs Can Help
Interoperability is moving ahead, but major health systems and hospitals in large population centers must ensure they don’t leave their smaller and more rural counterparts behind.